| INTRODUCTION
Esophageal cancer was listed as the sixth most common cause of cancer-related deaths worldwide with an increasing incidence rate. 1, 2 As one of the commonest cancers in north-central China, the majority of esophageal cancers are esophageal squamous cell carcinomas (ESCCs); here, the age-standardized annual incidence rate is >125/100 000. 3 Nearly all esophageal cancer patients are diagnosed at advanced stages and they face a poor prognosis; the cumulative mortality is approximately 25% for men and 20% for women. 4 ,5 ESCC's clinical characteristics, such as tumor-node-metastasis (TNM) stage and lymph node metastasis, were identified as prognostic factors for esophageal cancer. Moreover, some genetic factors also have a predictive value on esophageal cancer outcomes.
6,7
MicroRNA (miRNA) is a noncoding RNA with a nucleotide length of ∼22, and it is implicated in various biological processes such as embryonic development, cell differentiation, proliferation, apoptosis, cancer development, and insulin secretion. 8,9 miRNAs play important roles in cancer development, as they posttranscriptionally regulate the expression of tumor suppressor genes and proto-oncogenes. 8, 10, 11 During miRNA processing, the nuclear cleavage of long primary transcripts of miRNAs (pri-miRNAs) by the microprocessor complex, in- 
17-22
In the present study, we genotyped six miR-SNPs of miRNA processing machinery genes, including Dicer (rs3742330), RAN (rs14035), XPO5 (rs11077), TNRC6B (rs9623117), GEMIN3
(rs197412), and GEMIN4 (rs2740348), to evaluate their influence on ESCC.
| MATERIALS AND METHODS

| Tissue specimens and DNA extraction
Blood samples were collected from 128 ESCC patients who un- 
| Genotyping of miR-SNPs
The miR-SNP of the miRNA processing genes including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348) were genotyped as described previously, with the corresponding primers and probes. 21, 22 Briefly, the polymerase chain reaction (PCR)-ligase detection reaction (LDR) assay was performed to amplify the DNA fragments flanking miR-SNPs using the sequence provided in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/snp/). Ligation was performed using the different probes that were matched to the miR-SNPs, while the ligated products were separated using the ABI PRISM Genetic Analyzer 3730XL (Applied Biosystems, Foster City, CA, USA), which was used to detect the length difference of ligated products.
| Measurement of XPO5 levels in ESCC tissue
The The stained slides were semi-quantified by two pathologists who were blinded to the SNP data using HSCORE (19 was defined as a score of >100% and low expression was defined as a score of <100% ( Figure 1A and B). 
| Statistical analysis
| RESULTS
We genotyped these six miR-SNPs of the miRNA processing machinery genes including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348) in 128 ESCC patients and 120 healthy controls to evaluate the impact of these miR-SNPs on ESCC risk. No difference in allele distribution frequency of these miR-SNPs could be found between controls and ESCC patients by the χ 2 test. We subsequently assessed the prognostic value of these miR-SNPs on the overall survival of postoperative ESCC patients.
The Kaplan-Meier method was first performed to identify the clinical characteristics and ESCC stage associated with ESCC survival, as well as to display the association between ESCC stage and ESCC survival using the log-rank test (Table 1) . As for the miR-SNPs ( calculated; the rs11077 genotype-based XPO5 expression in ESCC patients is listed in Table 4 . The rs11077 AA genotype displayed a trend toward higher XPO5 expression when compared with the AC+CC genotype; this finding was of borderline statistical significance (P=.070).
A survival analysis related to XPO5 expression was performed; it was determined that patients with high XPO5 expression levels had a longer lifespan than did those patients with low XPO5 expression levels (5-year survival rate: 57.1% vs 33.3%, respectively; P=.045).
| DISCUSSION
